Promoted Content Promoted Content

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): ABNCoV2

            Therapeutic Area: Infections and Infectious Diseases Product Name: ABNCoV2

            Highest Development Status: Phase I Product Type: Vaccine

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable April 29, 2021

            Details:

            A neutralization test of samples from the study of ABNCoV2 has now confirmed similarly high levels of neutralizing antibodies against the SARS-CoV2 variants B.1.1.7 (British) and B.1.351 (South African).

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): ABNCoV2

            Therapeutic Area: Infections and Infectious Diseases Product Name: ABNCoV2

            Highest Development Status: Phase I Product Type: Vaccine

            Partner/Sponsor/Collaborator: Radhoud University Medical

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable March 08, 2021

            Details:

            The latest data confirm the previous strong immunogenicity results already published, and further demonstrate a protective efficacy of ABNCoV2 post-challenge with SARS-CoV-2.